Maldives Revises Drug Regulations to Permit Methylphenidate for ADHD Patients

In a landmark decision that promises to transform mental health care access for thousands of Maldives citizens, President Dr Mohamed Muizzu has officially amended the nation's primary pharmaceutical legislation to permit the use of methylphenidate—the gold-standard medication for Attention Deficit Hyperactivity Disorder—as a first-line treatment option for individuals diagnosed with the condition. 

The amendment, enacted through a Presidential Decree, represents the culmination of an extensive legislative process that began with scientific recommendation and concluded with unanimous parliamentary approval.

The decree amends the Drugs Act, specifically removing methylphenidate from the list of prohibited substances. This regulatory shift addresses a longstanding gap in the Maldives' healthcare infrastructure, where physicians have been legally constrained from prescribing the very medications recommended by international clinical guidelines for managing ADHD, forcing families to seek treatment abroad or rely on less effective alternatives.

The amendment process commenced when the National Drug Control Council—an autonomous body responsible for evaluating the medical, social, and economic implications of controlled substances—submitted a formal recommendation advocating for methylphenidate's reclassification based on comprehensive scientific evidence supporting its safety and efficacy when administered under proper medical supervision.

Following receipt of this recommendation, the matter entered the Cabinet's deliberative framework, where ministers examined the proposal's implications for public health, potential misuse considerations, and the administrative requirements for implementation. After thorough discussion, Cabinet members granted approval, authorising the submission of legislative amendments to the Parliament.

The Parliament ultimately voted to approve the removal of methylphenidate from the prohibited list, reflecting a consensus across political divides that prioritised patients' access to evidence-based treatments. 

ADHD represents one of the most prevalent neurodevelopmental conditions globally, affecting approximately seven percent of children and four percent of adults worldwide. While comprehensive prevalence data for the Maldives remains limited, mental health professionals throughout the country have reported increasing diagnoses over the past decade, coinciding with greater public awareness and improved diagnostic capabilities. The condition manifests through persistent patterns of inattention, hyperactivity, and impulsivity that substantially impair academic performance, occupational functioning, and interpersonal relationships when left untreated.

Methylphenidate, marketed internationally under brand names including Ritalin and Concerta, functions as a central nervous system stimulant that targets dopamine and norepinephrine pathways in the brain. Decades of clinical research have established the medication's effectiveness in reducing core ADHD symptoms, with response rates exceeding seventy percent among properly diagnosed patients.